Oveporexton: How Does It Treat Narcolepsy Type 1?

How does oveporexton treat narcolepsy type 1?

The FDA approved oveporexton, sold as Orzeyful, on August 5 for adults with narcolepsy type 1. Its distinctive feature is its mechanism: the oral medicine stimulates a receptor normally activated by orexin, a chemical messenger involved in maintaining wakefulness. The approval establishes a treatment that directly addresses impaired orexin signaling across the disorder's symptoms. [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms).

People with type 1 narcolepsy typically lose the brain cells that produce orexin. This can cause overwhelming daytime sleepiness, fragmented nighttime sleep and cataplexy, a sudden loss of muscle strength often triggered by laughter or other strong emotions. Activating the remaining receptors helps compensate for the missing signal; it does not establish that the lost neurons have regenerated or that the disorder is cured. Existing treatments, including sodium oxybate and pitolisant, can also address sleepiness and cataplexy through other mechanisms. [NIH narcolepsy overview](https://health.nih.gov/health-topics-a-z/narcolepsy).

What did the oveporexton clinical trials show?

The First Light and Radiant Light studies enrolled 168 and 105 participants, respectively. Both were randomized, placebo-controlled trials lasting 12 weeks. Researchers assessed the ability to remain awake during a standardized test, patient-reported sleepiness and weekly cataplexy episodes. Results published in the New England Journal of Medicine showed improvements across these measures. The studies were funded by Takeda, the drug's developer. [Phase 3 trial publication](https://www.nejm.org/doi/full/10.1056/NEJMoa2601598).

Across the treatment groups, median reductions from baseline in weekly cataplexy frequency ranged from approximately 79% to 89%, compared with approximately 28% to 39% with placebo. These figures describe reductions in episode frequency, not the proportion of patients cured. Because the comparator was placebo, the trials do not establish superiority over another active narcolepsy medicine. Their 12-week controlled duration also leaves questions about sustained benefit and uncommon adverse effects during years of treatment. [Published trial results](https://www.nejm.org/doi/full/10.1056/NEJMoa2601598).

What should patients know about safety and future uses?

Side effects were common enough to matter in treatment decisions. In pooled phase 3 data, insomnia occurred in 60% of participants receiving 2 mg twice daily, compared with 1% receiving placebo; increased urinary frequency occurred in 58% and 5%, respectively. Urinary urgency and excess saliva were also reported. The prescribing information additionally warns about elevations in creatine phosphokinase, an enzyme associated with muscle injury, and advises patients to report unexplained muscle pain, weakness or dark urine. [Orzeyful prescribing information](https://content.takeda.com/?contenttype=PI&country=USA&documentnumber=1&language=ENG&product=ORZ).

Medication review is essential because strong CYP3A inhibitors, which interfere with a pathway that metabolizes the drug, are contraindicated. Treatment selection also requires consideration of existing bladder symptoms and other medical conditions. Persistent insomnia or worsening urinary symptoms should prompt discussion with the prescribing clinician. [Prescribing precautions](https://content.takeda.com/?contenttype=PI&country=USA&documentnumber=1&language=ENG&product=ORZ).

The broader interest in orexin medicines extends to other disorders of excessive sleepiness. Takeda reports that another investigational compound, TAK-360, is being studied for narcolepsy type 2 and idiopathic hypersomnia, as well as type 1 narcolepsy. Those development programs concern a different molecule and do not establish that oveporexton treats those conditions. Each proposed use needs its own evidence of benefit and acceptable risk. [Takeda research update](https://www.takeda.com/newsroom/newsreleases/2026/nejm-oveporexton-narcolepsy-data/).